一棵小韭黄
2021-12-01
对抗新冠不知道，对抗韭菜效果一定很好！
ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609416034,"tweetId":"609416034","gmtCreate":1638317103271,"gmtModify":1638318740172,"author":{"id":3539941499659464,"idStr":"3539941499659464","authorId":3539941499659464,"authorIdStr":"3539941499659464","name":"一棵小韭黄","avatar":"https://static.tigerbbs.com/4d61c69f4072f0aa0cd3b56409d42f70","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>对抗新冠不知道，对抗韭菜效果一定很好！</p></body></html>","htmlText":"<html><head></head><body><p>对抗新冠不知道，对抗韭菜效果一定很好！</p></body></html>","text":"对抗新冠不知道，对抗韭菜效果一定很好！","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609416034","repostId":1123034178,"repostType":2,"repost":{"id":"1123034178","kind":"news","pubTimestamp":1638237802,"share":"https://www.laohu8.com/m/news/1123034178?lang=&edition=full","pubTime":"2021-11-30 10:03","market":"us","language":"en","title":"ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1123034178","media":"InvestorPlace","summary":"The omicron variant of Covid-19 has sent several pharmaceutical companies flying higher this past we","content":"<p>The omicron variant of Covid-19 has sent several pharmaceutical companies flying higher this past week, such as <b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) and <b>Pfizer</b>(NYSE:<b><u>PFE</u></b>). Today, shares of <b>Adagio Therapeutics</b>(NASDAQ:<b><u>ADGI</u></b>) are soaring higher by 80% after closing the previous trading session 34% higher. The company only has a market capitalization of $5 billion, but it issued a positive announcement concerning its SARS-CoV-2 antibody, ADG-20.</p>\n<p>Here’s what shareholders of ADGI stock should know as the omicron variant grabs hold of the market.</p>\n<p>ADGI Stock: What You Should Know</p>\n<p>While other vaccine makers are rushing to test vaccines in order to combat the omicron variant, Adagio’s ADG-20 antibody is reportedly already effective. The company stated that none of the mutations present in the spike protein of the omicron variant have been able to escape ADG-20 neutralization. The antibody was originally engineered to neutralize and anticipate mutations of the SARS-CoV-2 virus and future SARS-like viruses. Additionally, the antibody has several preferable characteristics, such as intramuscular administration and coverage of multiple variants.</p>\n<p>Laura Walker, cofounder of Adagio, added that:</p>\n<blockquote>\n “Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously.”\n</blockquote>\n<p>Morgan Stanley Ups Its Bet on Adagio</p>\n<p>Furthermore, Morgan Stanley raised itsprice targetto $49 from $33 on ADGI stock after news of the omicron variant surfaced. The higher price target reflects increased sales and market share. Analyst Matthew Harrison stressed that ADG-20 is highly effective against the omicron variant, beating out antibodies from pharmaceutical giants such as <b>Regeneron</b>(NASDAQ:<b><u>REGN</u></b>) and <b>Eli Lilly</b>(NYSE:<b><u>LLY</u></b>). Harrison also expects regulators to help fund Adagio’s interim trials to more quickly bring the antibody to market. As a result, Harrison estimates 2022 sales to reach $1.8 billion. Governments stockpiling an additional 4 million doses of the ADG-20 antibody will help it reach this target.</p>\n<p>According to<i>TipRanks</i>, Matthew Harrison has a success rate of 54% and an average return of 13.3% over a 1-year period. Harrison is ranked 579 out of 7,731 total analysts that<i>TipRanks</i>tracks. Interestingly enough, Harrison has a $60 price target for Pfizer, representing upside of 14%. He covers Moderna as well with a price target of $313, representing 15% downside.</p>\n<p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 10:03 GMT+8 <a href=https://investorplace.com/2021/11/adgi-stock-soars-as-analysts-lock-on-to-its-omicron-fighting-potential/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant of Covid-19 has sent several pharmaceutical companies flying higher this past week, such as Moderna(NASDAQ:MRNA) and Pfizer(NYSE:PFE). Today, shares of Adagio Therapeutics(NASDAQ:...</p>\n\n<a href=\"https://investorplace.com/2021/11/adgi-stock-soars-as-analysts-lock-on-to-its-omicron-fighting-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/11/adgi-stock-soars-as-analysts-lock-on-to-its-omicron-fighting-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123034178","content_text":"The omicron variant of Covid-19 has sent several pharmaceutical companies flying higher this past week, such as Moderna(NASDAQ:MRNA) and Pfizer(NYSE:PFE). Today, shares of Adagio Therapeutics(NASDAQ:ADGI) are soaring higher by 80% after closing the previous trading session 34% higher. The company only has a market capitalization of $5 billion, but it issued a positive announcement concerning its SARS-CoV-2 antibody, ADG-20.\nHere’s what shareholders of ADGI stock should know as the omicron variant grabs hold of the market.\nADGI Stock: What You Should Know\nWhile other vaccine makers are rushing to test vaccines in order to combat the omicron variant, Adagio’s ADG-20 antibody is reportedly already effective. The company stated that none of the mutations present in the spike protein of the omicron variant have been able to escape ADG-20 neutralization. The antibody was originally engineered to neutralize and anticipate mutations of the SARS-CoV-2 virus and future SARS-like viruses. Additionally, the antibody has several preferable characteristics, such as intramuscular administration and coverage of multiple variants.\nLaura Walker, cofounder of Adagio, added that:\n\n “Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously.”\n\nMorgan Stanley Ups Its Bet on Adagio\nFurthermore, Morgan Stanley raised itsprice targetto $49 from $33 on ADGI stock after news of the omicron variant surfaced. The higher price target reflects increased sales and market share. Analyst Matthew Harrison stressed that ADG-20 is highly effective against the omicron variant, beating out antibodies from pharmaceutical giants such as Regeneron(NASDAQ:REGN) and Eli Lilly(NYSE:LLY). Harrison also expects regulators to help fund Adagio’s interim trials to more quickly bring the antibody to market. As a result, Harrison estimates 2022 sales to reach $1.8 billion. Governments stockpiling an additional 4 million doses of the ADG-20 antibody will help it reach this target.\nAccording toTipRanks, Matthew Harrison has a success rate of 54% and an average return of 13.3% over a 1-year period. Harrison is ranked 579 out of 7,731 total analysts thatTipRankstracks. Interestingly enough, Harrison has a $60 price target for Pfizer, representing upside of 14%. He covers Moderna as well with a price target of $313, representing 15% downside.","news_type":1},"isVote":1,"tweetType":1,"viewCount":870,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609416034"}
精彩评论